Clinical trials: Asthma, Bronchial
Asthma
A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Non-steroidal Therapy.
This study is designed to determine if the investigational drug is effective and safe in individuals with asthma.
- Trial name
- NCT00603382
- Testing
- GW685698X
- Where
- 149 sites in United States, Bulgaria and 12 more
- Volunteers
- 599 people
- Sponsor
- GlaxoSmithKline
Asthma
Efficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate Asthma
The primary objective of this trial is to evaluate the efficacy and safety of tiotropium 1.25 mcg (2 actuations of 0.625 mcg), tiotropium 2.5 mcg (2 actuations of 1.25 mcg) and tiotropium 5 mcg (2 actuations of 2.5 mcg) once…
- Trial name
- NCT01122680
- Testing
- Tiotropium bromide
- Where
- 19 sites in United States, Germany and 3 more
- Volunteers
- 105 people
- Sponsor
- Boehringer Ingelheim
Asthma
Investigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER® Device in Adult Patients With Persistent Asthma
This study is designed to provide data about the 24 hours FEV1 profile, safety and tolerability of indacaterol/mometasone TWISTHALER device compared to placebo and using fluticasone/salmeterol as an active control.
- Trial name
- NCT00557440
- Testing
- fluticasone propionate/salmeterol, indacaterol maleate / mometasone furoate
- Where
- 6 sites in Belgium, Germany
- Volunteers
- 37 people
- Sponsor
- Novartis
Asthma
To Investigate the Effects of Altering the Time of Day of Dosing (Morning or Evening) With Fluticasone Furoate 100 Micrograms Once Daily Administered Via a Dry Powder Inhaler in Subjects With Asthma
This study will investigate the effects of altering the time of day of dosing (morning or evening) with Fluticasone Furoate 100 (FF 100) micrograms (mcg) once daily administered via a dry powder inhaler (DPI) in subjects with…
- Trial name
- NCT01808339
- Testing
- Fluticasone Furoate (FF)
- Where
- Australia
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline
Moderate to Severe Asthma
Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma
This is a Phase 3b, multicenter, randomized, double-blind, parallel group, placebo-controlled study designed to investigate the potential effect of tezepelumab (210 mg subcutaneous [SC] every 4 weeks [Q4W]) on antibody responses…
- Trial name
- VECTOR (NCT05062759)
- Testing
- Tezepelumab
- Where
- 15 sites in United States
- Volunteers
- 70 people
- Sponsor
- AstraZeneca
Respiratory Syncytial Virus
A Prospective, Epidemiological Study to Assess the Disease Burden of Respiratory Syncytial Virus Associated, Suspected Lower Respiratory Tract Infections in Newborns, From 0 to 2 Years of Age and Risk of Development of Wheeze and Asthma From 0 to 6 Years of Age
The purpose of this study is to assess the incidence and associated healthcare utilization of RSV-associated, suspected LRTI in a general population of infants from birth up to 2 years of age, and also to assess the accuracy of a…
- Trial name
- NCT01995175
- Testing
- Nasal swab sampling, Blood sampling, Diary cards
- Where
- 23 sites in United States, Argentina and 6 more
- Volunteers
- 2,409 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma
A Safety Extension Study With Benralizumab for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist
The purpose of this study is to continue to characterize the safety profile of benralizumab administration and monitor the pharmacodynamic activity of the drug in those asthma patients who remain on treatment for at least 16…
- Trial name
- MELTEMI (NCT02808819)
- Testing
- Benralizumab
- Where
- 178 sites in United States, Argentina and 13 more
- Volunteers
- 447 people
- Sponsor
- AstraZeneca
Asthma
Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma
The primary objective of this study was to evaluate the efficacy of fluticasone propionate multidose dry powder inhaler (Fp MDPI) and fluticasone propionate/salmeterol xinafoate multidose dry powder inhaler (FS MDPI) when…
- Trial name
- NCT02139644
- Testing
- FS MDPI, Fp MDPI, albuterol/salbutamol
- Where
- 140 sites in United States, Canada and 6 more
- Volunteers
- 787 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma, Aspirin-Induced
Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)
The purpose of this phase 2 study is to assess the safety and efficacy of oral ifetroban for the treatment of aspirin-exacerbated respiratory disease (AERD).
- Trial name
- NCT03028350
- Testing
- Ifetroban Oral Capsule
- Where
- 16 sites in United States
- Volunteers
- 54 people
- Sponsor
- Cumberland Pharmaceuticals
Asthma
Safety Study of Albuterol Spiromax® in Subjects With Asthma
The purpose of this study is to evaluate the safety of Albuterol Spiromax® over 52 weeks during two dosing periods: (1) a 12-week, double-blind, placebo-controlled QID dosing period followed by (2) a 40-week, open-label PRN…
- Trial name
- NCT01698320
- Testing
- Albuterol MDPI
- Where
- 30 sites in United States
- Volunteers
- 364 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma
The objective of this study is to evaluate the efficacy and safety of vilanterol inhalation powder administered once daily in the evening in adolescent and adult subjects 12 years of age and older with persistent asthma over a…
- Trial name
- NCT01181895
- Testing
- Vilanterol, Salmeterol Inhalation Powder
- Where
- 34 sites in United States, Germany and 3 more
- Volunteers
- 348 people
- Sponsor
- GlaxoSmithKline
Asthma
Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma
The purpose of this trial is to confirm the safety and clinical benefit of benralizumab administration in asthma patients with mild to moderate persistent asthma in order to gain an understanding of the benefit/risk of…
- Trial name
- NCT02322775
- Testing
- Benralizumab
- Where
- 57 sites in United States, Canada and 4 more
- Volunteers
- 211 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive, Bronchospasm
Prophylactic Efficacy of Relenza Against Influenza A and B
In response to the European regulatory authorities, GSK is conducting a post-marketing observational study to assess the efficacy of Relenza when used as prophylaxis against influenza. SPECIFIC AIMS 1.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Bronchospasm, Influenza, Human, Asthma
- Trial name
- NCT01156701
- Testing
- Receiving a prescription of Relenza for prophylaxis, No prophylaxis with Relenza
- Volunteers
- 171,705 people
- Sponsor
- GlaxoSmithKline
Asthma
Efficacy and Safety Study in Subjects With Asthma
The study is a multi-center, double-blind, placebo-controlled, cross-over study to evaluate the efficacy and safety of selected doses and dose intervals of the novel long acting beta agonist (LABA), GW642444 in asthmatic subjects…
- Trial name
- NCT00980200
- Testing
- Dose 4 QD, Dose 3 QD, Dose 2 QD
- Where
- 9 sites in United States
- Volunteers
- 75 people
- Sponsor
- GlaxoSmithKline
Asthma
Study of Efficacy and Safety of LOU064 in Inadequately Controlled Asthma Patients
This was a proof-of-concept study to evaluate the efficacy of LOU064 in patients with inadequately controlled asthma. All subjects were randomized with 3:2 ratio to receive LOU064 100 mg once daily or LOU064 matching placebo for…
- Trial name
- NCT03944707
- Testing
- LOU064 100 mg
- Where
- 19 sites in United States, Argentina and 3 more
- Volunteers
- 76 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily
To evaluate the efficacy, dose response and safety of four doses of GSK2190915 in tablet form (10mg, 30mg, 100mg and 300mg) administered once daily, over 8 weeks compared with placebo in adolescent and adult subjects (12 years of…
- Trial name
- NCT01147744
- Testing
- Fluticasone Propionate 100mcg via ACCUHALER/DISKUS, GSK2190915 100mg, GSK2190915 10mg
- Where
- 84 sites in United States, Bulgaria and 4 more
- Volunteers
- 700 people
- Sponsor
- GlaxoSmithKline
Asthma
A Safety and Efficacy Study of Tralokinumab in Adults With Asthma
The purpose of this study is to determine whether the addition of tralokinumab to standard asthma medication is effective in the treatment of adults with asthma.
- Trial name
- NCT01402986
- Testing
- Tralokinumab 300 mg, Q2W, Tralokinumab 300 mg, Q2/4W
- Where
- 89 sites in United States, Argentina and 13 more
- Volunteers
- 689 people
- Sponsor
- MedImmune LLC
Asthma
Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium
The purpose of this trial was to demonstrate that the efficacy of two treatment arms of the fixed-dose combination product QVM149 was non-inferior to the efficacy of the free combination arm of salmeterol/ fluticasone+ tiotropium…
- Trial name
- ARGON (NCT03158311)
- Testing
- QVM149, Salmeterol/fluticasone plus tiotropium
- Where
- 163 sites in Argentina, Chile and 18 more
- Volunteers
- 1,426 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma
The purpose of the trial was to evaluate the efficacy and safety of two different doses of QVM149 (QVM149 150/50/80 μg and QVM149 150/50/160 μg via Concept1) over two respective QMF149 doses (QMF149 150/160 μg and QMF149 150/320)…
- Trial name
- NCT02571777
- Testing
- QVM149 150/50/160, QVM149 150/50/80, QMF149 150/320
- Where
- 403 sites in Argentina, Austria and 39 more
- Volunteers
- 3,092 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Characteristics of Pts Initiating Spiriva Respimat in Asthma
This study is a cross-sectional, non-interventional study based on existing data (NISed).
- Trial name
- NCT03692676
- Testing
- Spiriva Respimat
- Where
- Germany
- Volunteers
- 116,133 people
- Sponsor
- Boehringer Ingelheim